A Phase 1/2 interventional study of Modufolin (arfolitixorin) and Fluorouracil in Colorectal Neoplasm, sponsored by Isofol Medical AB. Completed at 10 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-09.
Sponsored by Isofol Medical AB · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 159 studies testing fluorouracil in Colorectal Neoplasms — 15 open to participants now, 19 under way, 4 of them phase 3. Fluorouracil · Colorectal Neoplasms.
Among the 159 studies testing fluorouracil in Colorectal Neoplasms, this one is the 49th largest by enrollment of the 132 interventional ones that give a count, is one of 3 that started in 2014, is one of 7 in phase 1/2, and was the 123rd registered.
6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →15 of the 159 studies testing fluorouracil in Colorectal Neoplasms are open now, in 7 countries. Recruiting first, the newest first:
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Sites in China
Ages 18–75
West China Hospital · Sites in China
Ages 18–85
Shanghai Zhongshan Hospital · Sites in China
Ages 18–75
By country, each count listing its studies:
Fluorouracil: first FDA approval 1962 (FLUOROURACIL). What it is approved for, and how studies give it, is on its page →
Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
159 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 87 · Phase 3 41 · Phase 4 5
First in 1977; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 105 is above the median of 76 across 4,809 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 66 across the 132 interventional studies. Of the 110 that completed or were terminated, 18 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 159 have an industry lead sponsor. The 10 most frequent:
Isofol Medical AB is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Isofol Medical AB has 4 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
5 of the studies testing fluorouracil in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00335816Memorial Sloan Kettering Cancer CenterRadiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer | 2026-12 |
| NCT06654037National Cancer Institute (NCI)Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer | 2027-04-01 |
| NCT07158164Rutgers, The State University of New JerseyDPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment | 2027-07-07 |
| NCT07123441Sanjun CaiA Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer | 2027-09-01 |
| NCT06269978Arjun MittraIntraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer | 2027-09-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 159 studies testing fluorouracil in Colorectal Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose is to characterise the tolerability of Modufolin (arfolitixorin) in combination with 5-FU alone, in combination with 5-FU and Oxaliplatin, in combination with 5-FU and Irinotecan and in combination with 5-FU, Oxaliplatin and Bevacizumab.
Another purpose is to investigate 4 doses of Modufolin to identify the best dose for further assessment.
The study will investigate the tolerability of Modufolin at four (4) different dose levels (30 to 240 mg/m2) in therapy combinations with the chemotherapeutic agents 5-FU, Oxaliplatin +/- bevcizumab, and Irinotecan.
When the selected phase 2 dose is determined, 40 additional patients, will be included in the study in order to acquire more data on the safety and tolerability of Modufolin at this dose level. Twenty (20) of these additional patients will be treated in with Oxaliplatin, 20 with Irinotecan.
Inclusion Criteria:
Advanced colorectal (Stage IV) cancer verified by
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Modufolin in combination with 5-Fluorouracil only.
Drug: Modufolin (arfolitixorin) · Drug: Fluorouracil
Modufolin in combination with 5-Fluorouracil and Oxaliplatin according to Nordic FLOX regime
Drug: Modufolin (arfolitixorin) · Drug: Fluorouracil · Drug: Oxaliplatin
Modufolin in combination with 5-Fluorouracil and Irinotecan.
Drug: Modufolin (arfolitixorin) · Drug: Fluorouracil · Drug: Irinotecan
Modufolin in combination with 5-Fluorouracil and Oxaliplatin according to mFOLFOX-6 regime
Drug: Modufolin (arfolitixorin) · Drug: Fluorouracil · Drug: Oxaliplatin
Modufolin in combination with 5-Fluorouracil, Oxaliplatin and Bevacizumab
Drug: Modufolin (arfolitixorin) · Drug: Fluorouracil · Drug: Oxaliplatin · Drug: Bevacizumab
Modufolin in combination with 5-Fluorouracil and Irinotecan
Drug: Modufolin (arfolitixorin) · Drug: Fluorouracil · Drug: Irinotecan
IV injection every second week for 8 weeks.
Also known as: [6R] 5,10-methylenetetrahydrofolate, 6R-MTHF, 6R-methylene THF, ISO-901, arfolitixorin
IV injection every second week for 8 weeks.
Also known as: 5-FU, 5-Flourouacil, 5-Fluoro-1H,3H-pyrimidine-2,4-dione, Adrucil
IV infusion every second week for 8 weeks.
Also known as: Eloxatin, [(1R,2R)-cyclohexane-1,2-diamine](ethanedioato-O,O')platinum(II), Olatin, Oxamed, Oxitropic
IV infusion every second week for 8 weeks.
Also known as: (+)-(4S)-4,11-Dietyl-4-hydroxi-9-[(4-piperidinopiperidino)karbonyloxi]-1H-pyrano[3¢,4¢:6,7]indolizino[1,2-b]kinolin-3,14-(4H,12H)dion, Irinosor, Campto, Namedica
IV infusion every second week for 8 weeks.
Also known as: Avastin
Frequency and severity of dose limiting toxicity (DLT) or other Adverse Events (AE)
Primary safety variables will consist of monitoring and recording of DLTs and any significant AE that have led to adjustments in the therapy administration.
Time frame: The patients will be followed during 4 cycles of treatment (8 weeks).
Plan to share: No
Ran from Sep 2014 to primary completion in Jan 2020, 64 months.
Of 158 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 82. This study's 64 months is close to that.
Counting every sponsor, half of 260 studies reached it within 59 months; a quarter within 36 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: L-(+)-methylenetetrahydrofolic acid · Fluorouracil
Isofol Medical AB